Urinary p75^ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis

References

• Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.
   PubMed Web of Science ®Google Scholar
• Gibson SB, Figueroa KP, Bromberg MB, Pulst SM, Cannon-Albright L. Familial clustering of ALS in a population-based resource. Neurology 2014;82:17–22.
   PubMed Web of Science ®Google Scholar
• Olney NT, Spina S, Miller BL. Frontotemporal dementia. Neurol Clin. 2017;35:339–74.
   PubMed Web of Science ®Google Scholar
• Dechant G, Barde Y-A. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat Neurosci. 2002;5:1131–6.
   PubMed Web of Science ®Google Scholar
• Della-Bianca V, Rossi F, Armato U, Dal-Pra I, Costantini C, Perini G, et al. Neurotrophin p75 receptor is involved in neuronal damage by prion peptide-(106–126). J Biol Chem. 2001;276:38929–33.
   PubMed Web of Science ®Google Scholar
• Perini G, Della-Bianca V, Politi V, Della Valle G, Dal-Pra I, Rossi F, et al. Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med. 2002;195:907–18.
   PubMed Web of Science ®Google Scholar
• Nykjaer A, Willnow TE, Petersen CM. p75NTR-live or let die. Curr Opin Neurobiol. 2005;15:49–57.
   PubMed Web of Science ®Google Scholar
• Lowry KS, Murray SS, McLean CA, Talman P, Mathers S, Lopes EC, et al. A potential role for the p75 low-affinity neurotrophin receptor in spinal motor neuron degeneration in murine and human amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis and other motor neuron disorders: official publication of the World Federation of Neurology. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:127–34.
   PubMed Web of Science ®Google Scholar
• Seeburger JL, Tarras S, Natter H, Springer JE. Spinal cord motoneurons express p75NGFR and p145trkB mRNA in amyotrophic lateral sclerosis. Brain Res. 1993;621:111–5.
   PubMed Web of Science ®Google Scholar
• Copray JCVM, Jaarsma D, Kst BM, Bruggeman RWG, Mantingh I, Brouwer N, et al. Expression of the low affinity neurotrophin receptor p75 in spinal motoneurons in a transgenic mouse model for amyotrophic lateral sclerosis. Neuroscience 2003;116:685–94.
   PubMed Web of Science ®Google Scholar
• Ibáñez CF, Simi A. p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci. 2012;35:431–40.
   PubMed Web of Science ®Google Scholar
• Pehar M, Cassina P, Vargas MR, Castellanos R, Viera L, Beckman JS, et al. Astrocytic production of nerve growth factor in motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J Neurochem. 2004;89:464–73.
   PubMed Web of Science ®Google Scholar
• Turner BJ, Cheah IK, Macfarlane KJ, Lopes EC, Petratos S, Langford SJ, et al. Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem. 2003;87:752–63.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Chataway T, Schultz DW, Rush RA, Rogers ML. The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2014;9:e87398.
   PubMed Web of Science ®Google Scholar
• Trotti D, Rolfs A, Danbolt NC, Brown RH, Jr., Hediger MA. SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci. 1999;2:427–33.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Jia R, Shepheard S, Jin J, Hu F, Zhao X, Xue L, et al. Urinary extracellular domain of neurotrophin receptor p75 as a biomarker for amyotrophic lateral sclerosis in a Chinese cohort. Sci Rep. 2017;7:5127.
   PubMed Web of Science ®Google Scholar
• Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75(ECD): a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 2017;88:1137–43.
   PubMed Web of Science ®Google Scholar
• Rogers ML, Wuu J, Shepheard S, Chataway T, Schultz D, Anderson PM, et al. Urinary p75 neurotrophin receptor extracellular domain as a biomarker of symptomatic disease onset and progression. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:68–9.
   Google Scholar
• Shepheard S, Wiklendt L, Schultz D, Tan V, Chataway T, Wuu J, et al. Longitudinal changes in urinary p75 neurotrophin receptor extracellular domain levels as a disease progression biomarker in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:88–9.
   Google Scholar
• Benatar M, Boylan K, Jeromin A, Rutkove SB, Berry J, Atassi N, et al. ALS biomarkers for therapy development: state of the field and future directions. Muscle Nerve 2016;53:169–82.
   PubMed Web of Science ®Google Scholar
• Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol. 2002;12:260–7.
   PubMed Web of Science ®Google Scholar
• Pehar M, Cassina P, Vargas MR, Xie Y, Beckman JS, Massa SM, et al. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. Eur J Neurosci. 2006;24:1575–80.
   PubMed Web of Science ®Google Scholar
• Turner BJ, Rembach A, Spark R, Lopes EC, Cheema SS. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J Neurosci Res. 2003;74:605–13.
   PubMed Web of Science ®Google Scholar
• Massa SM, Xie Y, Yang T, Harrington AW, Kim ML, Yoon SO, et al. Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J Neurosci. 2006;26:5288–300.
   PubMed Web of Science ®Google Scholar
• Cheah IK, Cheema SS, Langford SJ, Lopes EC, Macfarlane KJ, Petratos S, et al. Design and application of a peptide nucleic acid sequence targeting the p75 neurotrophin receptor. Bioorg Med Chem Lett. 2003;13:2377–80.
   PubMed Web of Science ®Google Scholar
• Ito S, Ménard M, Atkinson T, Brown L, Whitfield J, Chakravarthy B. Relative expression of the p75 neurotrophin receptor, tyrosine receptor kinase A, and insulin receptor in SH-SY5Y neuroblastoma cells and hippocampi from Alzheimer’s disease patients. Neurochem Int. 2016;101:22–9.
   PubMed Web of Science ®Google Scholar
• Dowling P, Ming X, Raval S, Husar W, Casaccia-Bonnefil P, Chao M, et al. Up-regulated p75NTR neurotrophin receptor on glial cells in MS plaques. Neurology 1999;53:1676–82.
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Presley LN, Kordower JH. Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson’s disease: reduced cell numbers and co-localization with cholinergic neurons. Brain Res. 1991;539:19–30.
   PubMedGoogle Scholar
• Simmons DA, Mills BD, Butler Iii RR, Kuan J, McHugh TLM, Akers C, et al. Neuroimaging, urinary, and plasma biomarkers of treatment response in Huntington’s disease: preclinical evidence with the p75 ligand LM11A-31. Neurotherapeutics: J Am Soc Exp NeuroTher. 2021;18:1039–63.
   PubMed Web of Science ®Google Scholar
• Brito V, Giralt A, Enriquez-Barreto L, Puigdellívol M, Suelves N, Zamora-Moratalla A, et al. Neurotrophin receptor p75(NTR) mediates Huntington’s disease-associated synaptic and memory dysfunction. J Clin Invest. 2014;124:4411–28.
   PubMed Web of Science ®Google Scholar